This site is intended for healthcare professionals

Speciality hub

Neurology (CNS) and Pain

Containing dedicated Learning Zones, guidelines, trials and news for related conditions in Neurology (CNS) and Pain.

Read time: 5 mins

Last updated: 20th Jul 2020

Welcome:

Sign in/Register

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

Neurology is the branch of medicine that deals with conditions and diseases involving the central nervous system (brain and spinal cord) and the peripheral nervous systems (autonomic and somatic), including their coverings, blood vessels, and all effector tissue such as muscle.

Neurology encompasses over 5000 neurological diseases and relies on insights from fields such as neuroscience. This medical speciality deals with dementia including Alzheimer’s disease, Parkinson’s disease, neuromuscular disorders including spinal muscular atrophy and pain management as a sub-speciality.

Diseases in this section

Attention Deficit Hyperactivity Disorder (ADHD)

Containing relevant Learning Zones, guidelines, trials and news.

Dementia

Containing relevant Learning Zones, guidelines, trials and news.

Epilepsy

Containing relevant Learning Zones, guidelines, trials and news.

Neuromuscular Disorders

Containing relevant Learning Zones, guidelines, trials and news.

Pain

Containing relevant Learning Zones, guidelines, trials and news.

Parkinson's Disease

Containing relevant Learning Zones, guidelines, trials and news.

Learning Zones

Anticoagulation Therapy for Stroke Prevention

Learning Zone Homepage

Anticoagulation Therapy for Stroke Prevention

COMT inhibition in Parkinson’s Disease

Learning Zone Homepage

COMT inhibition in Parkinson’s Disease

Spinal Muscular Atrophy

Learning Zone Homepage

Spinal Muscular Atrophy

Neuroscience and Pain Learning Zone

Learning Zone Homepage

Neuroscience and Pain Learning Zone

Related news and insights

FDA accepts BLA from Eisai and Biogen for aducanumab, a proposed treatment for Alzheimer’s disease.

Biogen and Eisai, Co., Ltd. announced that the FDA has accepted the Biologics License Application (BLA) for aducanumab, an investigational treatment for Alzheimer’s disease.

1 mins

FDA approves Olinvyk for management of acute pain.- Trevena

The FDA has approved Olinvyk (oliceridine), from Trevena, an opioid agonist for the management of moderate to severe acute pain in adults, where the pain is severe enough to require an intravenous opioid and for whom alternative treatments are inadequate.

1 min

FDA approves Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older. Genentech/Roche

Genentech, a member of the Roche Group , announced that the FDA has approved Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and children 2 months of age and older.

1 min

See all news

Related drugs

Levetiracetam Mylan 1000 mg film-coated tablets

Levetiracetam Mylan 1000 mg film-coated tablets

Zebinix 800 mg tablets

Zebinix 800 mg tablets

Pregabalin Tillomed 75 mg capsules, hard

Pregabalin Tillomed 75 mg capsules, hard

Pregabalin Tillomed 50 mg capsules, hard

Pregabalin Tillomed 50 mg capsules, hard

Pregabalin Tillomed 300 mg capsules, hard

Pregabalin Tillomed 300 mg capsules, hard

Pregabalin Tillomed 25 mg capsules, hard

Pregabalin Tillomed 25 mg capsules, hard

Pregabalin Tillomed 225 mg capsules, hard

Pregabalin Tillomed 225 mg capsules, hard

Pregabalin Tillomed 200 mg capsules, hard

Pregabalin Tillomed 200 mg capsules, hard

Pregabalin Tillomed 150 mg capsules, hard

Pregabalin Tillomed 150 mg capsules, hard

Pregabalin Tillomed 100 mg capsules, hard

Pregabalin Tillomed 100 mg capsules, hard

Solpadeine Plus Tablets

Solpadeine Plus Tablets

Solpadeine Plus Capsules

Solpadeine Plus Capsules

solpadeine max tablets

solpadeine max tablets

Paramol Tablets

Paramol Tablets

Related Guidelines

Cannabis-based medicinal products

This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.

1 mins

Risk reduction and management of delirium

This guideline provides recommendations based on current evidence for best practice in the detection, assessment, treatment and follow up of adults with delirium, as well as reducing the risk of delirium.

1 min

Pharmacological management of migraine

This guideline provides recommendations on the pharmacological management of adults with acute migraine, and prophylaxis for patients with episodic or chronic migraine or medication overuse headache.

1 min

See all guidelines

Your peers are looking at...

FDA approves supplemental indication of Spravato for major depressive disorder with acute suicidal ideation or behavior. Johnson & Johnson

FDA approves supplemental indication of Spravato for major depressive disorder with acute suicidal ideation or behavior. Johnson & Johnson

1 mins

FDA accepts BLA from Eisai and Biogen for aducanumab, a proposed treatment for Alzheimer’s disease.

FDA accepts BLA from Eisai and Biogen for aducanumab, a proposed treatment for Alzheimer’s disease.

1 mins

FDA approves Olinvyk for management of acute pain.- Trevena

FDA approves Olinvyk for management of acute pain.- Trevena

1 mins

Phase III CheckMate -743 trial of Opdivo + Yervoy shows efficacy in malignant pleural mesothelioma.- BMS

Phase III CheckMate -743 trial of Opdivo + Yervoy shows efficacy in malignant pleural mesothelioma.- BMS

1 mins

Phase III ORIENT-11 trial of Tyvyt plus Alimta shows efficacy in NSCLC.- Innovent Biologics + Eli Lilly

Phase III ORIENT-11 trial of Tyvyt plus Alimta shows efficacy in NSCLC.- Innovent Biologics + Eli Lilly

1 mins

Pacira announces publication of Phase IV study of Exparel in cesarean section procedures in Anesthesia & Analgesia.

Pacira announces publication of Phase IV study of Exparel in cesarean section procedures in Anesthesia & Analgesia.

3 mins

Cimzia is the first and only biologic approved in Europe with the option for a reduced maintenance dose for patients across the full axial spondyloarthritis spectrum- UCB.

Cimzia is the first and only biologic approved in Europe with the option for a reduced maintenance dose for patients across the full axial spondyloarthritis spectrum- UCB.

1 mins

FDA approves Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older. Genentech/Roche

FDA approves Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older. Genentech/Roche

1 mins

FDA approves SOMATOM On.site, a mobile head computed tomography (CT) scanner from Siemens Healthineers.

FDA approves SOMATOM On.site, a mobile head computed tomography (CT) scanner from Siemens Healthineers.

1 mins

Genentech/Roche provides update on phase III study Of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer.

Genentech/Roche provides update on phase III study Of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer.

1 mins

Related Journals

The Association Between Vitamin D Status, Vitamin D Supplementation, Sunlight Exposure, and Parkinson's Disease: A Systematic Review and Meta-Analysis.

The Association Between Vitamin D Status, Vitamin D Supplementation, Sunlight Exposure, and Parkinson's Disease: A Systematic Review and Meta-Analysis.

1 mins

Assessing pain in non-intubated critically ill patients unable to self report: an adaptation of the Behavioral Pain Scale.

Assessing pain in non-intubated critically ill patients unable to self report: an adaptation of the Behavioral Pain Scale.

1 mins

Emergency Management of Epilepsy and Seizures.

Emergency Management of Epilepsy and Seizures.

1 mins

Executive function in eating disorders: The role of state anxiety

Executive function in eating disorders: The role of state anxiety

1 mins

Alemtuzumab depletion failure can occur in multiple sclerosis.

Alemtuzumab depletion failure can occur in multiple sclerosis.

1 mins

Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage.

Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage.

1 mins

Neuropathology of Alzheimer's disease.

Neuropathology of Alzheimer's disease.

1 mins

Therapeutic Monoclonal Antibodies: What Headache Specialists Need to Know.

Therapeutic Monoclonal Antibodies: What Headache Specialists Need to Know.

1 mins

Association of White Matter Structure With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.

Association of White Matter Structure With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.

1 mins

Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial.

Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial.

1 mins

Related Events

BNA 2021 Festival Of Neuroscience

BNA 2021 Festival Of Neuroscience

European Neurosurgery 2021

European Neurosurgery 2021

World Congress for Brain Mapping and Therapeutics of SBMT 2021 (SBMT 2021)

World Congress for Brain Mapping and Therapeutics of SBMT 2021 (SBMT 2021)

Related Clinical Trials

An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis (TOWER)

An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis (TOWER)

3 mins

Identification of a Biomarker Predictive of Evolution of Parkinson Disease (GLIAPARK)

Identification of a Biomarker Predictive of Evolution of Parkinson Disease (GLIAPARK)

3 mins

Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

3 mins

Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults (GWPCARE3)

Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults (GWPCARE3)

4 mins

Simvastatin in Secondary Progressive Multiple Sclerosis (MS-OPT)

Simvastatin in Secondary Progressive Multiple Sclerosis (MS-OPT)

3 mins

Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ?1 Month to <4 Years With Partial-onset Seizures

Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ?1 Month to <4 Years With Partial-onset Seizures

3 mins

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS)

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS)

1 mins

A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) (CLARITY)

A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) (CLARITY)

2 mins

Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

2 mins

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) in Relapsing Multiple Sclerosis (RMS)

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) in Relapsing Multiple Sclerosis (RMS)

3 mins

Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063) (ENLIGHTEN)

Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063) (ENLIGHTEN)

3 mins

Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies

Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies

4 mins